Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2025
0mins
Source: Newsfilter
Cash Dividend Announcement: Aerovate Therapeutics expects to declare a cash dividend of approximately $67.6 to $69.6 million for pre-Merger stockholders, pending board approval and the completion of its merger with Jade Biosciences.
Merger Details: The special meeting for Aerovate's stockholders to vote on the merger is scheduled for April 16, 2025, with the closing expected by April 30, 2025, subject to various approvals and conditions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
